Ecopia adds pancreatic cancer patients in ongoing trial

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Ecopia BioSciences, Inc. has received a No Objection Letter from the Therapeutics Products Directorate of Health Canada for the amendment to the ongoing phase 1 clinical trial of the company's anticancer agent, ECO-4601, allowing it to include pancreatic cancer patients.

The Montreal-based pharmaceutical company said this selective inclusion of pancreatic cancer patients is consistent with Ecopia's clinical plans to focus on fast-track opportunities, including glioma.

Recent supportive evidence shows that ECO-4601 is a potent inhibitor of the RAS-mitogen-activated protein kinase pathway, which is an important validated target for anticancer therapies, according to a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.